Charles River splits off and divests CDMO business

Charles River splits off and divests CDMO business

Charles River Laboratories International Inc. has sold off its CDMO business QS Pharma LLC, saying the small-molecule manufacturing business was “not optimized” within the firm's portfolio.

Charles River acquired QS Pharma as part of Ohio-based WIL Research Laboratories LLC in January 2016, for a total of for $586m cash.

However, as an early-stage contract research organization (CRO), Charles River stated that QS Pharma was “not optimized within its portfolio at current scale”, in the firm’s end of year report.

Amy Cianciaruso, a spokesperson for Charles River, told Outsourcing-Pharma that Pennsylvania-based QS Pharma accounted for less than 10% of WIL Research’s total revenue.

Instead, QS Pharma was sold to the UK-based outsourcing specialist Quotient Clinical Ltd., which is looking to expand its US presence.

The value of $75m USD was generated from the sale, which Charles River said could be deployed for use in other “long-term” growth opportunities.

When asked about why Charles River wanted to acquire WIL Research, Cianciaruso explained: “WIL Research was an exceptional strategic fit for Charles River because it incorporated the key attributes we require in an acquisition: high-quality services, scientific expertise, complementary capabilities, and access to growing end markets.”

“The addition broadened our portfolio in safety assessment services and bioanalysis. It also expanded our geographic safety assessment footprint, particularly in continental Europe, providing needed capacity to meet current and future demand,” she added.

In the report, Charles River also says the acquisitions of Blue Stream Laboratories and WIL Research’s CDMO services contributed 9.2% to Manufacturing revenue growth in Q4 of 2016. 

The transaction of QS Pharma completed February 10.

 

(Image: iStock/Radachynskyi)

Related News

Brexit and EU regulations motivate Quotient US buyouts

Brexit and EU regulations motivate Quotient US buyouts

Charles River re-ups Chiesi drug discovery contract

Charles River re-ups Chiesi drug discovery contract

Charles River to pay $1.8m to settle overbilling claims

Charles River to pay $1.8m to settle overbilling claims

The NCG model was developed using CRISPR gene editing technology. (Image: Charles River Laboratories)

Charles River launches first CRISPR-generated immunodeficient model

The partnership aims to advance programs in immunology, metabolic disorders, and oncology. (Image: iStock/Pinkypills)

Charles River partnership goes beyond traditional FFS model, says Nimbus

Charles River has expanded its oncology discovery business. (Image: iStock/unoL)

Charles River partners with CRO to expand PDX model capabilities

Recro Gainesville is an FDA- and DEA-approved solid oral dose manufacturing services provider. (Image: iStock/dolgachov)

CDMO Recro expands manufacturing capabilities at former Alkermes site

The acquisition adds to Charles River's early-stage capabilities in bioanalytical services. (Image: iStock/Bogdanhoda)

Charles River continues CRO buy up, acquires Agilux Labs for $64m

The acquisition is the latest in a series. (Image: iStock)

Charles River acquires analytical CRO

The alliance between Charles River and Genentech dates back to 2005. (Image: iStock/AlexRaths)

Charles River extends drug discovery alliance with Genentech

Charles River filed a Form 8-K report with the SEC yesterday. (Image: iStock/Hakat)

Charles River files with SEC as WIL Research acquisition is finalized

(Image: iStock/verdateo)

Charles River partners with Milner Therapeutics Institute and Consortium

(Image: iStock/Tsyhun)

Charles River strategic partnership to populate R&D pipeline, shorten timelines

Related Products

See more related products